Progression of Ebola Therapeutics During the 2014-2015 Outbreak

被引：52
作者：
Mendoza, Emelissa J. [1 ,2 ]
Qiu, Xiangguo [1 ,3 ]
Kobinger, Gary P. [1 ,2 ,3 ,4 ]
机构：
[1] Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB, Canada
[2] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada
[4] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
来源：
TRENDS IN MOLECULAR MEDICINE | 2016年 / 22卷 / 02期
基金：
加拿大健康研究院;
关键词：
VIRUS DISEASE; CONVALESCENT PLASMA; HEMORRHAGIC-FEVER; NONHUMAN-PRIMATES; PATIENT; FAVIPIRAVIR; AMIODARONE; GLYCOPROTEIN; INFECTION; FAILURE;
D O I：
10.1016/j.molmed.2015.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The recent Ebola virus (EBOV) outbreak in West Africa was the deadliest EBOV epidemic in history, highlighting the need for a safe and efficacious treatment against EBOV disease (EVD). In the absence of an approved treatment, experimental drugs were utilized under compassionate grounds hoping to diminish EVD-associated morbidity and mortality. As more data were collected from safety studies, Phase II/III clinical trials were introduced in Guinea, Sierra Leone, and Liberia to test promising candidates, including small-molecule drugs, RNA based treatments, and antibody-based therapies. In this review, we summarize the use of, and preliminary observations from, current clinical trials with EVD therapeutics, shedding light on experimental drug selection, emergency clinical evaluation, and the impact these factors may have on future infectious disease outbreaks.
引用
收藏
页码：164 / 173
页数：10
相关论文
共 58 条
[1]   Favipiravir for children with Ebola [J].
Bouazza, Naim ;
Treluyer, Jean-Marc ;
Foissac, Frantz ;
Mentre, France ;
Taburet, Anne-Marie ;
Guedj, Jeremie ;
Anglaret, Xavier ;
de Lamballerie, Xavier ;
Keita, Sakoba ;
Malvy, Denis ;
Frange, Pierre .
LANCET, 2015, 385 (9968) :603-604
[2]   Selecting the Right Tool For the Job [J].
Caplan, Arthur L. ;
Plunkett, Carolyn ;
Levin, Bruce .
AMERICAN JOURNAL OF BIOETHICS, 2015, 15 (04) :4-10
[3]  
ClinicalTrials.gov, 2015, PHAS 3 EFF SAF STUD
[4]  
ClinicalTrials.gov, 2015, CLIN TRIAL EV EFF SA
[5]  
ClinicalTrials.gov, 2014, SAF TOL PHARM 1 HUM
[6]  
ClinicalTrials.gov, 2014, CLIN STUD ASS EFF SA
[7]  
ClinicalTrials.gov, 2015, SAF PHARM SINGL ZMAP
[8]  
ClinicalTrials.gov, 2014, EFF FAV EB JIKI
[9]  
ClinicalTrials.gov, 2014, OP LAB MULT STUD SAF
[10]  
ClinicalTrials.gov, 2015, EM EV CONV PLASM EB
123456